This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pollak, A.
Right arrow Articles by Widness, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pollak, A.
Right arrow Articles by Widness, J. A.
Related Collections
Right arrow Blood

PEDIATRICS Vol. 107 No. 1 January 2001, pp. 78-85

Effect of Intravenous Iron Supplementation on Erythropoiesis in Erythropoietin-Treated Premature Infants

Received Aug 31, 1999; accepted Apr 13, 2000.

Arnold Pollak*, Michael Hayde*, Marianne HaynDagger , Kurt Herkner*, Kenneth A. Lombard§, Gert Lubec*, Manfred Weninger*, and John A. Widnessparallel

From the * Department of Neonatology, University Children's Hospital, Vienna, Austria; Dagger  Institute for Biochemistry, University of Graz, Austria; § Department of Pediatrics, Barbara Bush Children's Hospital at Maine Medical Center, Portland, Maine; and the parallel  Department of Pediatrics, University of Iowa, College of Medicine, Iowa City, Iowa.

Objective.  To test the efficacy and safety of combining intravenous iron in amounts approximating the in utero iron accretion rate and the postnatal iron loss with erythropoietin (EPO) in very low birth weight (VLBW) infants.

Methods.  A prospective, controlled, randomized, unmasked trial lasting 21 days was performed in 29 clinically stable VLBW infants <31 weeks' gestation and <1300 g birth weight not treated with red blood cell transfusions during the study period. Mean (± standard error of the mean) age at study entry was 23 ± 2.9 days. After a 3-day run-in baseline period in which all participants received oral supplements of 9 mg/kg/day of iron polymaltose complex (IPC), participants were randomized to receive 18 days of treatment with: 1) oral IPC alone (oral iron group); 2) 300 U of recombinant human EPO (r-HuEPO) kg/day and daily oral IPC (EPO + oral iron group); 3) 2 mg/kg/day of intravenous iron sucrose, r-HuEPO, and oral iron (intravenous iron + EPO group). To assess efficacy of the 3 treatments, serial blood samples were analyzed for hemoglobin (Hb), hematocrit (Hct), reticulocyte count, red blood cell indices and plasma levels of transferrin, transferrin receptor (TfR), ferritin, and iron. Oxidant injury was assessed before and after treatment by plasma and urine levels of malondialdehyde (MDA) and o-tyrosine.

Results.  At the end of treatment, Hb, Hct, reticulocyte count, and plasma TfR were markedly higher in both of the EPO-treated groups, compared with the oral iron group. At study exit a trend toward increasing Hb and Hct levels and significantly higher reticulocyte counts were observed in the intravenous iron + EPO group, compared with the EPO + oral iron group. During treatment, plasma ferritin levels increased significantly in the intravenous iron + EPO group and decreased significantly in the other 2 groups. By the end of treatment, ferritin levels were significantly higher in the intravenous iron + EPO group compared with the other 2 groups. Although plasma and urine MDA or o-tyrosine did not differ among the 3 groups, plasma MDA was significantly greater in the subgroup of intravenous iron + EPO participants sampled at the end of the 2-hour parenteral iron infusion, compared with values observed immediately before and after parenteral iron-dosing.

Conclusions.  In stable VLBW infants receiving EPO treatment, parenteral supplementation with 2 mg/kg/day of iron sucrose results in a small, but significant, augmentation of erythropoiesis beyond that of r-HuEPO and enteral iron alone. However, to reduce the potential adverse effects of parenteral iron/kg/day on increasing plasma ferritin levels and on causing oxidative injury, we suggest that the parenteral iron dose used should be reduced and/or the time of infusion extended to maintain a serum iron concentration below the total iron-binding capacity.  Key words:  intravenous, iron supplementation, erythropoiesis, erythropoietin-treated infants, very low birth weight infants.




This article has been cited by other articles:


Home page
 Arch. Dis. Child.Home page
F C Ridley, J Harris, R Gottstein, and A J B Emmerson
Is supplementary iron useful when preterm infants are treated with erythropoietin?
Arch. Dis. Child., December 1, 2006; 91(12): 1036 - 1038.
[Full Text] [PDF]

Home page
 PediatricsHome page
N. Haiden, J. Schwindt, F. Cardona, A. Berger, K. Klebermass, M. Wald, C. Kohlhauser-Vollmuth, B. Jilma, and A. Pollak
Effects of a Combined Therapy of Erythropoietin, Iron, Folate, and Vitamin B12 on the Transfusion Requirements of Extremely Low Birth Weight Infants
Pediatrics, November 1, 2006; 118(5): 2004 - 2013.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
J. A. Widness, R. E. Serfass, N. Haiden, S. E. Nelson, K. A. Lombard, and A. Pollak
Erythrocyte Iron Incorporation but Not Absorption Is Increased by Intravenous Iron Administration in Erythropoietin-Treated Premature Infants
J. Nutr., July 1, 2006; 136(7): 1868 - 1873.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
N. Haiden, K. Klebermass, F. Cardona, J. Schwindt, A. Berger, C. Kohlhauser-Vollmuth, B. Jilma, and A. Pollak
A Randomized, Controlled Trial of the Effects of Adding Vitamin B12 and Folate to Erythropoietin for the Treatment of Anemia of Prematurity
Pediatrics, July 1, 2006; 118(1): 180 - 188.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
G. R. Aronoff
Safety of Intravenous Iron in Clinical Practice: Implications for Anemia Management Protocols
J. Am. Soc. Nephrol., December 1, 2004; 15(suppl_2): S99 - S106.
[Full Text] [PDF]

Home page
 PediatricsHome page
M. P. Meyer, H. Donato, P. Rendo, L. Prudent, N. Vain, R. K. Ohls, and R. A. Ehrenkranz
Erythropoietin and Preemies
Pediatrics, December 1, 2002; 110(6): 1253 - 1255.
[Full Text] [PDF]

Home page
 Arch Pediatr Adolesc MedHome page
S. Nazir, R. L. Peverini, D. D. Deming, A. O. Hopper, and N. R. Vyhmeister
Comparison of 2 Iron Doses in Infants Receiving Recombinant Human Erythropoietin Therapy
Arch Pediatr Adolesc Med, June 1, 2002; 156(6): 540 - 544.
[Abstract] [Full Text] [PDF]